secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125455
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics Q3 net loss $11.9M; ENLIGHTEN 2 topline due Q2 2025
---------------------------------------------------------------------

- Cash & equivalents $51.6M as of Sep 30, 2024; runway into Q1 2026.
- R&D expenses fell to $5.9M from $12.4M YoY; G&A down to $3.9M from $5.0M.
- ENLIGHTEN 2 pivotal trial fully enrolled Oct 2024; topline results expected Q2 2025.
- ENLIGHTEN 1 extension study showed no product-related serious adverse events.
- Net loss improved to $11.9M vs $15.7M in Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017024125455/0000950170-24-125455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017024125455/lyra-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer